{
  "validated_facts": [
    {
      "drug_name": "sertraline",
      "condition_name": "major depressive disorder",
      "relation": "TREATS",
      "outcome": "efficacy and acceptability",
      "side_effects": [],
      "effect_size": "",
      "confidence_interval": "",
      "source_id": "Lancet",
      "section": "Summary",
      "span": "Sertraline might be the best choice when starting treatment for moderate to severe major depression in adults because it has the most favourable balance between benefits, acceptability, and acquisition cost.",
      "confidence": 0.9
    },
    {
      "drug_name": "Fluvoxamine",
      "condition_name": "major depressive disorder",
      "relation": "EQUIVALENT_TO",
      "outcome": "response rate",
      "side_effects": [],
      "effect_size": "31/109 vs 33/108",
      "confidence_interval": "OR 0.90 (0.50-1.62)",
      "source_id": "Lancet",
      "section": "results",
      "span": "Fluvoxamine vs Citalopram: response rate 31/109 vs 33/108, OR 0.90 (0.50-1.62)",
      "confidence": 0.9
    },
    {
      "drug_name": "Fluvoxamine",
      "condition_name": "major depressive disorder",
      "relation": "ASSOCIATED_WITH_SE",
      "outcome": "dropout rate",
      "side_effects": [],
      "effect_size": "29/109 vs 22/108",
      "confidence_interval": "OR 1.42 (0.75-2.66)",
      "source_id": "Lancet",
      "section": "results",
      "span": "Fluvoxamine vs Citalopram: dropout rate 29/109 vs 22/108, OR 1.42 (0.75-2.66)",
      "confidence": 0.9
    },
    {
      "drug_name": "Fluoxetine",
      "condition_name": "major depressive disorder",
      "relation": "EQUIVALENT_TO",
      "outcome": "response rate",
      "side_effects": [],
      "effect_size": "83/141 vs 83/143",
      "confidence_interval": "OR 1.03 (0.64-1.66)",
      "source_id": "Lancet",
      "section": "results",
      "span": "Fluoxetine vs Fluvoxamine: response rate 83/141 vs 83/143, OR 1.03 (0.64-1.66)",
      "confidence": 0.9
    },
    {
      "drug_name": "Milnacipran",
      "condition_name": "major depressive disorder",
      "relation": "SUPERIOR_TO",
      "outcome": "response rate",
      "side_effects": [],
      "effect_size": "32/56 vs 40/57",
      "confidence_interval": "OR 0.57 (0.26-1.23)",
      "source_id": "Lancet",
      "section": "results",
      "span": "Milnacipran vs Fluvoxamine: response rate 32/56 vs 40/57, OR 0.57 (0.26-1.23)",
      "confidence": 0.9
    },
    {
      "drug_name": "Venlafaxine",
      "condition_name": "major depressive disorder",
      "relation": "SUPERIOR_TO",
      "outcome": "response rate",
      "side_effects": [],
      "effect_size": "14/34 vs 48/77",
      "confidence_interval": "OR 0.42 (0.19-0.96)",
      "source_id": "Lancet",
      "section": "results",
      "span": "Venlafaxine vs Fluvoxamine: response rate 14/34 vs 48/77, OR 0.42 (0.19-0.96)",
      "confidence": 0.9
    },
    {
      "drug_name": "escitalopram",
      "condition_name": "major depressive disorder",
      "relation": "TREATS",
      "outcome": "",
      "side_effects": [],
      "effect_size": "",
      "confidence_interval": "",
      "source_id": "Lancet",
      "section": "discussion",
      "span": "escitalopram and sertraline might be the best choice when starting a treatment for moderate to severe major depression because they have the best possible balance between efficacy and acceptability",
      "confidence": 0.9
    },
    {
      "drug_name": "sertraline",
      "condition_name": "major depressive disorder",
      "relation": "TREATS",
      "outcome": "",
      "side_effects": [],
      "effect_size": "",
      "confidence_interval": "",
      "source_id": "Lancet",
      "section": "discussion",
      "span": "escitalopram and sertraline might be the best choice when starting a treatment for moderate to severe major depression because they have the best possible balance between efficacy and acceptability",
      "confidence": 0.9
    },
    {
      "drug_name": "reboxetine",
      "condition_name": "major depressive disorder",
      "relation": "CONTRAINDICATED_FOR",
      "outcome": "",
      "side_effects": [],
      "effect_size": "",
      "confidence_interval": "",
      "source_id": "Lancet",
      "section": "discussion",
      "span": "reboxetine should not be used as a routine first-line acute treatment for major depression",
      "confidence": 0.9
    }
  ],
  "total_facts": 9,
  "validation_summary": {
    "original_count": 9,
    "valid_count": 9,
    "invalid_count": 0,
    "warning_count": 0
  }
}